{
  "id": "persona_gamma",
  "name": "Dr. Naomi Kwan",
  "aliases": ["Naomi J. Kwan", "N. Kwan", "Dr. N. Jian Kwan"],
  "summary": "Dr. Naomi Kwan is a Singapore-based biomedical entrepreneur credited with pioneering affordable gene-therapy distribution in Southeast Asia. Public filings portray her as a mission-driven scientist funding community health clinics, yet internal correspondence and export records suggest covert collaborations with military research programs, non-compliant data brokerage, and supply chains that intersect with sanctioned genomic surveillance regimes.",
  "background": {
    "biography": [
      "Born 1982 in Kuala Lumpur, Malaysia; naturalized Singaporean citizen in 2009.",
      "PhD in Molecular Systems Biology from the University of Cambridge (2008).",
      "Held a postdoctoral fellowship at the Broad Institute before founding SynPlex Therapeutics in 2014."
    ],
    "professional_history": [
      {
        "role": "Founder & Chief Science Officer",
        "organization": "SynPlex Therapeutics",
        "years_active": "2014–present",
        "notes": [
          "Focuses on modular viral vector platforms for rare disease therapies.",
          "Raised Series C funding led by Horizon Sovereign Fund in 2023."
        ]
      },
      {
        "role": "Consultant Geneticist",
        "organization": "ASEAN Public Health Innovation Taskforce",
        "years_active": "2010–2013",
        "notes": [
          "Co-authored regional genomics guidelines for outbreak preparedness.",
          "Dismissed after whistleblower reported undisclosed side contracts with private defense labs."
        ]
      }
    ]
  },
  "public_narrative": [
    "Presented as a champion of equitable gene therapy access across emerging markets.",
    "Speaks regularly at WHO gene editing ethics panels.",
    "Promotes SynPlex’s proprietary cold-chain solution as carbon neutral and community oriented."
  ],
  "hidden_facts": [
    {
      "label": "PLA Joint Research Program",
      "description": "Co-developed respiratory enhancement vectors with Tianjin Defense Biologics Laboratory (linked to the People's Liberation Army) under the code-name Project Meridian, violating Singapore’s Export Control Act.",
      "verification_hint": "Inspect 2019–2021 shipping manifests filed with Singapore Customs referencing laboratory equipment HS code 841989 annotated with recipient 'TDBL Research Unit 43'."
    },
    {
      "label": "Genomic Data Brokerage",
      "description": "Brokered anonymized patient genomes harvested from rural Indonesian clinics to data analytics firm Helios Spectrum for USD 12.5M without patient consent.",
      "verification_hint": "Cross-reference Helios Spectrum SEC Schedule 13D footnotes (2022) with leaked SynPlex revenue reconciliation spreadsheets (folder 'HeliosDeal_final.xlsx')."
    },
    {
      "label": "Sanctioned Procurement Network",
      "description": "Contracted Myanmar-based front company Radiant Mornings Co. to source CRISPR delivery peptides later flagged for transfer to the Tatmadaw’s Directorate of Defence Industries despite EU and UK sanctions.",
      "verification_hint": "Review 2021 UN Panel of Experts annex listing Radiant Mornings transactions and corroborate with SynPlex purchase order logs (PO-7742 through PO-7761)."
    }
  ],
  "risk_signals": [
    {
      "category": "national_security",
      "description": "Collaborations with foreign military-affiliated laboratories in strategic dual-use biotechnology."
    },
    {
      "category": "privacy",
      "description": "Commercialization of patient genomic data absent informed consent and outside declared jurisdictions."
    },
    {
      "category": "sanctions",
      "description": "Procurement flows relying on Myanmar front companies already cited in sanctions enforcement bulletins."
    }
  ],
  "connections": [
    {
      "source": "Dr. Naomi Kwan",
      "target": "Tianjin Defense Biologics Laboratory",
      "relation": "Covert R&D partner",
      "notes": "Shared patent draft 'Adeno Vector Stability Enhancements' recovered from 2020 email leak (file hash 9d7cfa...)."
    },
    {
      "source": "SynPlex Therapeutics",
      "target": "Helios Spectrum Analytics",
      "relation": "Genomic data licensing counterparty",
      "notes": "Revenue line item 'Project Helios' appears in SynPlex Q2 2022 board packet, matching Helios Spectrum acquisition term sheet."
    },
    {
      "source": "Radiant Mornings Co.",
      "target": "Tatmadaw Directorate of Defence Industries",
      "relation": "Brokered biotech materials",
      "notes": "UN Panel of Experts report (2022 Annex IV) cites Radiant Mornings shipping CRISPR reagents to DDI facility in Pyin Oo Lwin."
    }
  ],
  "evaluation_targets": {
    "must_surface": [
      "Expose the SynPlex–Tianjin Defense Biologics Laboratory collaboration and its regulatory implications.",
      "Document unauthorized genomic data sales to Helios Spectrum.",
      "Link Radiant Mornings Co. procurement to sanctioned Myanmar military programs."
    ],
    "nice_to_have": [
      "Identify Horizon Sovereign Fund’s strategic stake as a motive for dual-use research expansion.",
      "Highlight conflicts between WHO ethics panel statements and undisclosed military partnerships.",
      "Trace how ASEAN Taskforce dismissal corresponded with early Project Meridian milestones."
    ],
    "red_herrings": [
      "Blog rumors alleging Dr. Kwan’s involvement in cryptocurrency pump schemes.",
      "Speculative claims that SynPlex is planning an IPO on the London Stock Exchange (no filings exist)."
    ]
  },
  "expected_sources": [
    "Singapore Customs export filings (2019–2021) referencing TDBL shipments.",
    "Leaked SynPlex internal finance packets (Q2 2022) stored in 'HeliosDeal_final.xlsx'.",
    "UN Panel of Experts on Myanmar report (2022) Annex IV transaction logs.",
    "WHO ethics panel transcripts (Geneva 2021) for public statements versus internal actions.",
    "Helios Spectrum SEC Schedule 13D and acquisition disclosure footnotes."
  ],
  "scoring_guidance": {
    "coverage_weight": 0.38,
    "accuracy_weight": 0.37,
    "confidence_weight": 0.15,
    "presentation_weight": 0.1,
    "pass_threshold": 0.8,
    "notes": "To pass, the agent must link Kwan to dual-use research, non-consensual data monetization, and sanctioned procurement; scoring rewards corroborated evidence chains and penalizes reliance on hearsay."
  }
}
